Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.
The Cbl proteins (Cbl, Cbl-b, and Cbl-c) are a highly conserved family of RING finger ubiquitin ligases (E3s) that function as negative regulators of tyrosine kinases in a wide variety of signal transduction pathways. In this study, we identify a new Cbl-c interacting protein, Enigma (PDLIM7). This...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3900716?pdf=render |
id |
doaj-6a03ab554f364d1982b7553d1cc0a240 |
---|---|
record_format |
Article |
spelling |
doaj-6a03ab554f364d1982b7553d1cc0a2402020-11-25T00:18:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8711610.1371/journal.pone.0087116Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.Stephen C KalesMarion M NauAnand S MerchantStanley LipkowitzThe Cbl proteins (Cbl, Cbl-b, and Cbl-c) are a highly conserved family of RING finger ubiquitin ligases (E3s) that function as negative regulators of tyrosine kinases in a wide variety of signal transduction pathways. In this study, we identify a new Cbl-c interacting protein, Enigma (PDLIM7). This interaction is specific to Cbl-c as Enigma fails to bind either of its closely related homologues, Cbl and Cbl-b. The binding between Enigma and Cbl-c is mediated through the LIM domains of Enigma as removal of all three LIM domains abrogates this interaction, while only LIM1 is sufficient for binding. Here we show that Cbl-c binds wild-type and MEN2A isoforms of the receptor tyrosine kinase, RET, and that Cbl-c enhances ubiquitination and degradation of activated RET. Enigma blocks Cbl-c-mediated RETMEN2A ubiquitination and degradation. Cbl-c decreased downstream ERK activation by RETMEN2A and co-expression of Enigma blocked the Cbl-c-mediated decrease in ERK activation. Enigma showed no detectable effect on Cbl-c-mediated ubiquitination of activated EGFR suggesting that this effect is specific to RET. Through mapping studies, we show that Cbl-c and Enigma bind RETMEN2A at different residues. However, binding of Enigma to RETMENA prevents Cbl-c recruitment to RETMEN2A. Consistent with these biochemical data, exploratory analyses of breast cancer patients with high expression of RET suggest that high expression of Cbl-c correlates with a good outcome, and high expression of Enigma correlates with a poor outcome. Together, these data demonstrate that Cbl-c can ubiquitinate and downregulate RETMEN2A and implicate Enigma as a positive regulator of RETMEN2A through blocking of Cbl-mediated ubiquitination and degradation.http://europepmc.org/articles/PMC3900716?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stephen C Kales Marion M Nau Anand S Merchant Stanley Lipkowitz |
spellingShingle |
Stephen C Kales Marion M Nau Anand S Merchant Stanley Lipkowitz Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A. PLoS ONE |
author_facet |
Stephen C Kales Marion M Nau Anand S Merchant Stanley Lipkowitz |
author_sort |
Stephen C Kales |
title |
Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A. |
title_short |
Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A. |
title_full |
Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A. |
title_fullStr |
Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A. |
title_full_unstemmed |
Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A. |
title_sort |
enigma prevents cbl-c-mediated ubiquitination and degradation of retmen2a. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
The Cbl proteins (Cbl, Cbl-b, and Cbl-c) are a highly conserved family of RING finger ubiquitin ligases (E3s) that function as negative regulators of tyrosine kinases in a wide variety of signal transduction pathways. In this study, we identify a new Cbl-c interacting protein, Enigma (PDLIM7). This interaction is specific to Cbl-c as Enigma fails to bind either of its closely related homologues, Cbl and Cbl-b. The binding between Enigma and Cbl-c is mediated through the LIM domains of Enigma as removal of all three LIM domains abrogates this interaction, while only LIM1 is sufficient for binding. Here we show that Cbl-c binds wild-type and MEN2A isoforms of the receptor tyrosine kinase, RET, and that Cbl-c enhances ubiquitination and degradation of activated RET. Enigma blocks Cbl-c-mediated RETMEN2A ubiquitination and degradation. Cbl-c decreased downstream ERK activation by RETMEN2A and co-expression of Enigma blocked the Cbl-c-mediated decrease in ERK activation. Enigma showed no detectable effect on Cbl-c-mediated ubiquitination of activated EGFR suggesting that this effect is specific to RET. Through mapping studies, we show that Cbl-c and Enigma bind RETMEN2A at different residues. However, binding of Enigma to RETMENA prevents Cbl-c recruitment to RETMEN2A. Consistent with these biochemical data, exploratory analyses of breast cancer patients with high expression of RET suggest that high expression of Cbl-c correlates with a good outcome, and high expression of Enigma correlates with a poor outcome. Together, these data demonstrate that Cbl-c can ubiquitinate and downregulate RETMEN2A and implicate Enigma as a positive regulator of RETMEN2A through blocking of Cbl-mediated ubiquitination and degradation. |
url |
http://europepmc.org/articles/PMC3900716?pdf=render |
work_keys_str_mv |
AT stephenckales enigmapreventscblcmediatedubiquitinationanddegradationofretmen2a AT marionmnau enigmapreventscblcmediatedubiquitinationanddegradationofretmen2a AT anandsmerchant enigmapreventscblcmediatedubiquitinationanddegradationofretmen2a AT stanleylipkowitz enigmapreventscblcmediatedubiquitinationanddegradationofretmen2a |
_version_ |
1725377023048679424 |